Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression

European Heart Journal
Tomas G NeilanDesmond J Fitzgerald

Abstract

The use of doxorubicin (DOX) as a chemotherapeutic agent is limited by cardiac injury. Iloprost, a stable synthetic analogue of prostacyclin, has previously been shown to protect against DOX-induced cardiomyocyte injury in vitro. Here, we addressed whether iloprost is cardioprotective in vivo and whether it compromises the anti-tumour efficacy of DOX. Lewis Lung Carcinoma cells were implanted subcutaneously in the flank of C57BL/6 mice. DOX treatment was commenced from when tumours became visible. Iloprost was administered from prior to DOX treatment until sacrifice. Echocardiography and invasive haemodynamic measurements were performed immediately before sacrifice. As expected, DOX induced cardiac cell apoptosis and cardiac dysfunction, both of which were attenuated by iloprost. Also, iloprost alone had no effect on tumor growth and indeed, did not alter the DOX-induced suppression of this growth. In a murine model, iloprost attenuated the acute cardiac injury and dysfunction induced by DOX therapy without compromising its chemotherapeutic effect.

References

Dec 1, 1992·Biochemical Pharmacology·J CummingsJ F Smyth
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Sep 24, 1998·The New England Journal of Medicine·P K Singal, N Iliskovic
Oct 12, 1999·JAMA : the Journal of the American Medical Association·K M SheehanF E Murray
Jun 7, 2000·The Journal of Clinical Investigation·C S WilliamsR N DuBois
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C MertensL L Robison
Apr 3, 2002·The Journal of Biological Chemistry·Chuan-Ming HaoMatthew D Breyer
Apr 20, 2002·Science·Yan ChengGarret A FitzGerald
Jun 27, 2003·The Journal of Biological Chemistry·Kotha SubbaramaiahAndrew J Dannenberg

❮ Previous
Next ❯

Citations

Oct 24, 2009·Journal of Applied Physiology·Anna A BirukovaKonstantin G Birukov
Aug 20, 2009·Cardiology in Review·Kuldeep Maradia, Maya Guglin
Apr 14, 2006·European Heart Journal·Paul G HoranPascal P McKeown
Aug 13, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Alvaro MordenteElisabetta Meucci
Sep 14, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Merry L LindseyGregory J Aune
May 23, 2013·American Journal of Physiology. Endocrinology and Metabolism·Vernon W DolinskyJason R B Dyck
Oct 23, 2018·F1000Research·J Emanuel Finet, W H Wilson Tang
Jan 10, 2019·JACC. Basic to Translational Science·Albert Z LuuSubodh Verma
Sep 29, 2011·The Journal of Surgical Research·Michael ScullyAnthony J Cunningham
Jun 28, 2018·ACS Applied Materials & Interfaces·Yongzhi MenWuli Yang
Nov 28, 2012·Archives of Cardiovascular Diseases·Jean-Jacques Monsuez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

© 2022 Meta ULC. All rights reserved